Jun 20, 2019 / 12:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the BeiGene Midyear 2019 Clinical Data Wrap-Up Call to discuss the company's many recent data presentations. (Operator Instructions) I must advise you that this conference is being recorded today, June 20, 2019.
I would now like to turn the call over to your first speaker, Mr. Howard Liang. Thank you. Please go ahead.
Heng Liang - BeiGene, Ltd. - CFO & Chief Strategy Officer
Good morning, good afternoon, good evening. Welcome to BeiGene's Mid-2019 Medical Conference Wrap-Up Call. I'm Howard Liang, Chief Financial Officer and Chief Strategy Officer at BeiGene. We're holding this call to review the clinical data on zanubrutinib and tislelizumab presented or being presented at ASCO, EHA and ICML.
As a reminder, we'll be making forward-looking statements during today's event, and our business carries certain risks, some of these are discussed in our SEC filing.
Slide 4. Today's call will begin with introduction by our CEO and Chairman, John Oyler; followed by Dr. Jane
Beigene Ltd Conference Call to Discuss Clinical Data on Zanubrutinib at 15th International Conference on Malignant Lymphoma (ICML) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers